These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
251 related articles for article (PubMed ID: 25061279)
1. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Nathan SD; King CS Drug Des Devel Ther; 2014; 8():875-85. PubMed ID: 25061279 [TBL] [Abstract][Full Text] [Related]
2. Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. Behr J; Nathan SD; Harari S; Wuyts W; Kirchgaessler KU; Bengus M; Gilberg F; Wells AU Respir Med; 2018 May; 138():13-20. PubMed ID: 29724385 [TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Pitsiou G; Papakosta D; Bouros D Respiration; 2011; 82(3):294-304. PubMed ID: 21677422 [TBL] [Abstract][Full Text] [Related]
5. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Corte TJ; Wort SJ; Wells AU Sarcoidosis Vasc Diffuse Lung Dis; 2009 Jul; 26(1):7-19. PubMed ID: 19960783 [TBL] [Abstract][Full Text] [Related]
6. The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. Lee J; Song JU J Korean Med Sci; 2020 Mar; 35(8):e48. PubMed ID: 32103644 [TBL] [Abstract][Full Text] [Related]
7. Pulmonary Hypertension Exacerbated by Nintedanib Administration for Idiopathic Pulmonary Fibrosis. Shimomura I; Abe M; Li Y; Tsushima K; Sakao S; Tanabe N; Ikusaka M; Tatsumi K Intern Med; 2019 Apr; 58(7):965-968. PubMed ID: 30568123 [TBL] [Abstract][Full Text] [Related]
8. Iron deposition and increased alveolar septal capillary density in nonfibrotic lung tissue are associated with pulmonary hypertension in idiopathic pulmonary fibrosis. Kim KH; Maldonado F; Ryu JH; Eiken PW; Hartman TE; Bartholmai BJ; Decker PA; Yi ES Respir Res; 2010 Apr; 11(1):37. PubMed ID: 20398288 [TBL] [Abstract][Full Text] [Related]
9. Pulmonary hypertension in idiopathic pulmonary fibrosis does not influence six-minute walk distance: results from a retrospective study. Harari S; Caminati A; Cassandro R; Conti S; Madotto F; Luisi F; Cesana G Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jan; 31(4):297-305. PubMed ID: 25591141 [TBL] [Abstract][Full Text] [Related]
13. Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. Collum SD; Amione-Guerra J; Cruz-Solbes AS; DiFrancesco A; Hernandez AM; Hanmandlu A; Youker K; Guha A; Karmouty-Quintana H Can Respir J; 2017; 2017():1430350. PubMed ID: 28286407 [TBL] [Abstract][Full Text] [Related]
14. Right Ventricular Structure and Function in Idiopathic Pulmonary Fibrosis with or without Pulmonary Hypertension. D'Andrea A; Stanziola A; Di Palma E; Martino M; D'Alto M; Dellegrottaglie S; Cocchia R; Riegler L; Betancourt Cordido MV; Lanza M; Maglione M; Diana V; Calabrò R; Russo MG; Vannan M; Bossone E Echocardiography; 2016 Jan; 33(1):57-65. PubMed ID: 26096076 [TBL] [Abstract][Full Text] [Related]
19. Strategies for treating idiopathic pulmonary fibrosis. du Bois RM Nat Rev Drug Discov; 2010 Feb; 9(2):129-40. PubMed ID: 20094055 [TBL] [Abstract][Full Text] [Related]
20. Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Yan W; Peng LY; Ban CJ; Xu XF; Zhu M; Liu Y; Zhang S; Zhai ZG; Wang C; Dai HP Chin Med J (Engl); 2015 Apr; 128(7):896-901. PubMed ID: 25836609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]